Search
Cerus Corp
CERSAdd to Watchlist
3.160USD
+0.160+5.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
633.00MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.33%
5 Days
+8.22%
1 Month
+13.26%
6 Months
+60.41%
Year to Date
+53.40%
1 Year
+105.19%
Key Figures
3.037Open
3.205High
3.30MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.65%Turnover Ratio
3.000Prev. Close
3.030Low
6.10MTurnover
LossP/E Static
9.37P/B
0.00%Div Yield TTM
-4.45%ROA
3.15052wk High
1.38Volume Ratio
-20.92MNet Profit
200.32MShares
-0.0492EPS TTM
1.73Beta
-15.52%ROE
1.15052wk Low
5.83%Amplitude
56.98%Gross Margin
633.00MMarket Cap
1.90Reward/Risk
3.96%Risk Rate
TradingKey Stock Score of Cerus Corp
Currency: USD Updated: 2026-07-02Key Insights
Cerus Corp's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 50 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.50.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cerus Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Cerus Corp Highlights
StrengthsRisks
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25.16% year-on-year.
Undervalued
The company’s latest PE is -64.24, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 147.40M shares, increasing 2.95% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 12.37M shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
4.500
Target Price
+50.00%
Upside Space
Cerus Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cerus Corp Info
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Ticker SymbolCERS
CompanyCerus Corp
CEOGreenman (William M)
Websitehttps://www.cerus.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Cerus Corp (CERS)?
The current price of Cerus Corp (CERS) is 3.16.
What is the symbol of Cerus Corp?
The ticker symbol of Cerus Corp is CERS.
What is the 52-week high of Cerus Corp?
The 52-week high of Cerus Corp is 3.15.
What is the 52-week low of Cerus Corp?
The 52-week low of Cerus Corp is 1.15.
What is the market capitalization of Cerus Corp?
The market capitalization of Cerus Corp is 633.00M.
Is Cerus Corp (CERS) currently rated as Buy, Hold, or Sell?
According to analysts, Cerus Corp (CERS) has an overall rating of Buy, with a price target of 4.50.
What is the Earnings Per Share (EPS TTM) of Cerus Corp (CERS)?
The Earnings Per Share (EPS TTM) of Cerus Corp (CERS) is -0.08.